Trials and therapies in secondary progressive MS, simplified

Navid Manouchehri, Olaf Stüve

Research output: Contribution to journalComment/debatepeer-review

7 Scopus citations


The FDA approvals of siponimod and cladribine for secondary progressive multiple sclerosis raise questions about the diagnostic criteria for multiple sclerosis phenotypes and their applicability to clinical trials. A simpler classification for the disease could be the answer.

Original languageEnglish (US)
Pages (from-to)431-432
Number of pages2
JournalNature Reviews Neurology
Issue number8
StatePublished - Aug 1 2019

ASJC Scopus subject areas

  • Clinical Neurology
  • Cellular and Molecular Neuroscience


Dive into the research topics of 'Trials and therapies in secondary progressive MS, simplified'. Together they form a unique fingerprint.

Cite this